Identification and Characterization of Neoplastic Cells in Keratin-Positive Giant Cell-Rich Tumors
Maarten van der LindeiD, John S.A. ChrisingeriD, Elizabeth G. DemiccoiD, Carina Anja DehneriD, Gregory W. CharvilleiD, Inge H. Briaire‐de BruijniD, Sushama VarmaiD, Chenchen ZhuiD, Magdalena MatusiakiD, Judith V.M.G. BovéeiD, Matt van de RijniD, David G.P. van IJzendoorniD
Abstract
Keratin-positive giant cell-rich tumor (KPGCT) is a newly described bone and soft tissue tumor. The tumor is characterized by scattered keratin-positive cells and the presence of HMGA2::NCOR2 fusions. It is not known if the HMGA2::NCOR2 fusion is located in the keratin-positive cells, and little is known about how KPGCT develops. KPGCT shares some histologic features with tenosynovial giant cell tumor (TGCT), a soft tissue tumor with CSF1 rearrangements. Single-nuclei RNA sequencing (snRNA-seq) and Xenium spatial transcriptomics were used to elucidate the mechanisms driving KPGCT and compare KPGCT to TGCT. We show that the neoplastic cells in KPGCT constitute only a minority of cells in the tumor, and that they co-express keratin, HMGA2 and CSF1. The neoplastic cells in KPGCT express no synovial markers, confirming KPGCT as a distinct entity, separate from TGCT. The bulk of the tumor consists of CSF1R-expressing macrophages and osteoclast-like giant cells, suggesting an important role for CSF1-CSF1R signaling. In addition, we find that the cells with the HMGA2 translocation show activation of the hippo signaling pathway, which is known to regulate CSF1 expression. We show that the CSF1-CSF1R axis, possibly regulated through the hippo signaling pathway, plays an important role in KPGCT. This axis likely stimulates the migration and proliferation of macrophages, which form the majority of cells in the tumor, as well as their differentiation into osteoclasts-like giant cells. These results provide a rationale for the use of CSF1R inhibitors, which have already shown efficacy in TGCT, as a therapy for KPGCT. SignificanceKeratin-positive giant cell-rich tumor (KPGCT) is a rare, newly described soft tissue and bone tumor. By examining this tumour on a single-cell level, we confirm the identity of the neoplastic cells on a molecular level, showing these form a minority of cells in the tumor. We show that activation of the hippo pathway in the neoplastic cells is a likely driver of tumorigenesis. Additionally, we show the neoplastic cells produce large amounts of CSF1, attracting the macrophages that form the majority of cells in the tumor. This finding gives supporting evidence for anecdotal reports of response to CSF1 inhibitor therapy. Finally, we identify key differences between KPGCT and tenosynovial giant cell tumor, a tumor that shares histological features with KPGCT.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 1
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Interactions in CSF1-driven Tenosynovial Giant Cell Tumors
D. G. P. van IJzendoorn, M. Matusiak, … M. van de Rijn·Clinical Cancer ResearchPeer-reviewed·Aug 25, 2022
- Receptor tyrosine kinase inhibitors trametinib and axitinib effectively target the neoplastic component of giant cell tumor of bone in vitro
Veronika Knechtova, Michal Mahdal, … Jakub Neradil·bioRxiv·Oct 6, 2026
- Keratin 5 marks cancer-propagating cells sustained by an osteopontin-producing niche in high-grade serous ovarian carcinoma
Mallikarjun Bidarimath, Coulter Q. Ralston, … Alexander Yu. Nikitin·Cancer Heterogeneity and PlasticityPeer-reviewed·Apr 25, 2026
- PDGFRA Defines the Mesenchymal Stem Cell Kaposi’s Sarcoma Progenitors by Enabling KSHV Oncogenesis in an Angiogenic Environment
J. Naipauer, S. Rosario, … E. Mesri·bioRxiv·Oct 2, 2019
- Kaposi Sarcoma Herpes Virus Reprograms Mesenchymal Cell Glycosylation to control platelet-derived growth factor receptor A signaling
Julián Gambarte Tudela, Patricia N. Gutiérrez, … Diego Omar Croci·bioRxiv·Jun 30, 2026
- Aberrant paracrine signalling for bone remodelling underlies the mutant histone-driven giant cell tumour of bone.
L. Cottone, L. Ligammari, … A. M. Flanagan·Cell Death & DifferentiationPeer-reviewed·Aug 3, 2022